15
29th CINP World
Congress 2014
Tuesday, 24 June 2014
| Preliminary Scientific Programme
S-15
e
Symposium
10:00 – 12:00
Topic: Neurodegenerative disorders:
Parkinson, Alzheimer, Huntington,
Fronto-Temporal Dementia, Vascular Dementia (A)
Track: Translational
BACE1 in Alzheimer’s disease pathogenesis and drug
development
Chair:
Weihong Song, Canada
Co-chair: Jianping Jia, People’s Republic of China
GSK3 signaling regulates BACE1 expression and APP
processing and its pharmaceutical potential for Alzheim-
er’s disease drug development
Weihong Song, Canada
Alteration of BACE1 processing of APP in Alzheimer’s
disease
Kari Stefansson, Iceland
Inhibition of BACE1 for benefiting AD patients
Ruqiang Yan, USA
BACE1 SNPs and clinical trials in China
Jianping Jia, People’s Republic of China
W-5
e
Educational Workshop
10:00 – 11:00
Understanding modern genetics
W-6
e
Educational Workshop
11:10 – 12:10
Optimising drug trial design
Korean Session
10:00 – 12:00
PL-04
e
Plenary Lecture
14:00 – 14:45
Brain science using iPS cell technology and transgenic non-
human primates
Hideyuki Okano, Japan
S-16
e
Symposium
15:00 – 17:00
Topic: Depression (A)
Track: Translational
New basic and clinical developments for treatment Resistant
Depression
Chair:
Alan Frazer, USA
Co-chair: Siegfried Kasper, Austria
Drug development in treatment-resistant depression:
Current progress, major hurdles and future strategies
Carlos Zarate, USA
TRD: Results of a European multi-centre study
Siegfried Kasper, Austria
Potential of mGlu2/3 receptor antagonists for treatment-
resistant depression: An alternative to Ketamine
Shigeyuki Chaki, Japan
Neurochemical and behavioral effects of vagal nerve
stimulation
Alan Frazer, USA
S-17
e
Symposium
15:00 – 17:00
Topic: Schizophrenia (A)
Track: Translational
Novel glutamatergic treatment approaches for schizophre-
nia: Pharmacology, imaging and clinical trials
Chair:
Gerhard Gründer, Germany
Co-chair: Dean F. Wong, USA
Challenges for novel treatment approaches in schizophrenia
Gerhard Gründer, Germany
The pharmacological basis for novel glutamatergic treat-
ments
Daniel C. Javitt, USA
Characterization of novel glutamatergic treatments with
PET imaging
Dean F. Wong, USA
Clinical results with novel glutamatergic treatments
Daniel Umbricht, Switzerland
